Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome

This study tests MP0533, a new multi-targeted drug designed to attack multiple proteins on leukemia cells at once, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has relapsed or stopped responding to prior treatments. **You may be eligible if...** - You are 18 or older - You have relapsed or refractory AML or MDS (as defined by current medical guidelines) - Your overall health is adequate (ECOG score 0–2) with an expected survival of at least 12 weeks - Your white blood cell count, kidney, and liver function meet the required thresholds - You are using effective contraception (if applicable) **You may NOT be eligible if...** - Your white blood cell count is above 15G/L at the time of treatment - You have severe organ dysfunction - You are pregnant or breastfeeding - You have received certain recent treatments that would exclude participation Talk to your doctor to see if this trial is right for you.